Zentalis Pharmaceuticals (ZNTL) Receivables (2019 - 2024)

Name: Zentalis Pharmaceuticals (ZNTL) Receivables (2019 - 2024) | Business Quant
Creator: Business Quant

Zentalis Pharmaceuticals' quarterly Receivables came in at $5.0 million in Q4 2024, up 110.35% quarter-over-quarter from $2.4 million in Q4 2021.

Zentalis Pharmaceuticals has reported Receivables for 4 years, with the latest figure at $5.0 million in Q4 2024.

For the quarter ending Q4 2024, Receivables changed N/A year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2024 stood at $5.0 million (changed N/A YoY), and the FY2024 full-year result was $5.0 million, changed N/A from the prior year.
Receivables for Q4 2024 stood at $5.0 million, up from $2.4 million in the prior quarter.
The five-year high for Receivables was $82.1 million in Q1 2020, with the low at $5000.0 in Q2 2021.
Average Receivables over 3 years is $13.8 million, with a median of $2.4 million recorded in 2021.
Peak annual rise in Receivables reached 1272.97% in 2021, while the deepest fall reached 97.11% in 2021.
Tracing ZNTL's Receivables over 3 years: stood at $417000.0 in 2020, then soared by 470.02% to $2.4 million in 2021, then surged by 110.35% to $5.0 million in 2024.
The last three Receivables figures came in at $5.0 million (Q4 2024), $2.4 million (Q4 2021), and $3.0 million (Q3 2021), per Business Quant data.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	13.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	4.15 Mn
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	2.00 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	5.73 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	883.96 Mn
10	Zentalis Pharmaceuticals	280.35 Mn	280.35 Mn	-	-

Download Data 🔒